↓ Skip to main content

Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History

Overview of attention for article published in Journal of Clinical Oncology, March 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
8 news outlets
blogs
3 blogs
twitter
32 X users
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History
Published in
Journal of Clinical Oncology, March 2017
DOI 10.1200/jco.2016.70.9709
Pubmed ID
Authors

Amit Sud, Hauke Thomsen, Kristina Sundquist, Richard S. Houlston, Kari Hemminki

Abstract

Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history. Patients and Methods Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-specific family history of cancer. Interactions between family history of cancer and HL treatment were evaluated under additive and multiplicative models. Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53). The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35 years of age was 13.8%. We observed no significant difference in cancer risk over successive time periods. The risk of all second cancers was 1.3-fold higher for HL survivors with a first-degree relative with cancer ( P < .001), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and breast cancers, respectively. Moreover, a greater than additive interaction between family history of lung cancer and HL treatment was shown ( P = .03). Conclusion HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in individuals with a family history of cancer. This information should be used to inform risk-adapted therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.

X Demographics

X Demographics

The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 101 100%

Demographic breakdown

Readers by professional status Count As %
Other 13 13%
Student > Ph. D. Student 12 12%
Researcher 11 11%
Student > Bachelor 9 9%
Student > Master 7 7%
Other 19 19%
Unknown 30 30%
Readers by discipline Count As %
Medicine and Dentistry 46 46%
Nursing and Health Professions 7 7%
Biochemistry, Genetics and Molecular Biology 6 6%
Social Sciences 3 3%
Agricultural and Biological Sciences 1 <1%
Other 6 6%
Unknown 32 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 98. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2021.
All research outputs
#431,511
of 25,382,440 outputs
Outputs from Journal of Clinical Oncology
#859
of 22,051 outputs
Outputs of similar age
#9,197
of 322,532 outputs
Outputs of similar age from Journal of Clinical Oncology
#22
of 292 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,051 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 292 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.